Biopharma Royalty Powerhouse Dips Despite Beat-And-Raise Quarter

Ligand's stock experienced a decline at the beginning of Thursday following the release of their quarterly earnings report which surpassed expectations. Despite a strong performance in both earnings and sales, the biopharma royalty giant faced a dip in its stock value. The company's enduring strength was reflected in achieving better-than-expected results, attracting investor attention despite the setback in stock performance.